!

# REGEIVED CENTRAL FAX CENTER

JAN 2 0 2006

FAX TRANSMISSION		
DATE: January 20, 2006		
PTO IDENTIFIER: Application Number 10/002,854-Conf. #3669 Patent Number		
Inventor: Mark C. Poznansky et al.		
MESSAGE TO: US Patent and Trademark Office		
FAX NUMBER: (571) 273-8300		
FROM: EDWARDS ANGELL PALMER & DODGE LLP		
Melissa Hunter-Ensor, Ph.D.		
PHONE: (617) 439-4444		
Attorney Dkt. #: 62053CIP(51588)		
PAGES (Including Cover Sheet): 8		
CONTENTS: Transmittal (1 page) Pec Transmittal (1 page) Petition under 37 CFR 1.181 (4 pages) Certificate of Transmission (1 page)		
If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 439-4444 and send the original transmission to us by return mail at the address below.		
This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.		
EDWARDS ANGELL PALMER & DODGE LLP Three Stamford Plaza, 301 Tresser Boulevard, Suite 1310, Stamford, Connecticut 06901 Telephone: (203) 975-7505 Facsimile: (203) 975-7180		
ļ		

Approved for use through 07/31/2006, OM8 0651-0031 U. S. Putont and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Progressive Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMR control number. Application No. (if known): 10/002,854 Attorney Docket No.: 62053CIP(51588) Certificate of Transmission under 37 CFR 1.8 I hereby certify that this correspondence is being facsimile transmitted to the United Stales Patent and Trademark Office. January 20, 2006 Date Eileen M. Woodbury Typed or printed name of person signing Certificate (617) 439-4444 Registration Number, if applicable Telephone Number Each paper must have its own certificate of transmission, or this certificate must Note: identify each submitted paper. Transmittal (1 page) Fee Transmittal (1 page) Petition under 37 CFR 1.181 (4 pages)

# RECEIVED CENTRAL FAX CENTER

## JAN 20 2006

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0051-0031
U.S. Palent and Trudemark Office; U.S. DEPARTMENT OF COMMERCE
Under the Pupprwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/002,854-Conf. #3669 Filing Date TRANSMITTAL November 1, 2001 First Named Inventor **FORM** Mark C. Poznansky Art Unit 1651 (to be used for all correspondence after initial filing) Examiner Namo L. B. Lankford Altorney Docket Number Total Number of Pages in This Submission 62053CIP(51588) ENCLOSURES (Check all that apply) X Fee Transmiltal Form Drawing(s) After Allowance Communication Fee Attached Appeal Communication to Board of Licensing-related Papers Appeals and Interferences Amendment/Reply Appeal Communication to TC Pelition under 37 CFR 1.181 (Appeal Notice, Brief, Reply Brief) Pelition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Change of Correspondence Address Affidavits/declaration(s) Status Letter X Other Enclosure(s) (please Identify below): Extension of Time Request Terminal Disclaimer Express Abandonment Request Reguest for Refund Chargo \$400.00 to deposit account No. 04-1105 Information Disclosure Statement CD. Number of CD(s) Cartified Capy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53

I horoby certify that this corresponde	nce is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (571) 273-
8300, on the date shown below.	C .
Dated: January 20, 2006	Signature: Qoo (Eilean M. Woodbury)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Reg. No.

55,289

EDWARDS ANGELL PALMER & DORGE LLP

Melissa Hunter-Ensor, Ph.D.

January 20, 2006

Firm Name

Signature

Dale

Printed name

A MARINE A

# JAN 2 0 2006

PTO/SB/17p (11-04)

	149/10 Per 10/ Care 1/1/04/1/1/10 1/2007, ONID 0631:0011
	U.S. Patrol and Trademorb Officer 11 S. DEDARTMENT or commence
Under the Paperson's Payletties Act of some As a some and the state of the sound of	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it displays a valid OMB control number.
and the triperwork Reduction Act of 1885, no person are required	O f85000d to a collection of information unlaws at displays a scaled Ohio analyst
	The state of the s

#### PETITION FEE 10/002,854-Conf. #3669 **Application Number** Under 37 CFR 1.17(f), (g) & (h) November 1, 2001 **Filing Date** TRANSMITTAL (Free are subject to annual revision) Mark C. Poznansky First Named Inventor Send completed form to: Commissioner for Palents P.O. Box 1450 Alexandria, VA 22313-1450 1651 Art Unit L. B. Lankford Examiner Name 62053CIP(51588) Attorney Docket Number

Enclosed is a petition filed under 37 CFR 1.181 that requires a processing fee (37 CFR 1.17(f)), (g), or (h)). Payment of \$ 400.00 is enclosed.  This form should be included with the above-mantioned petition and faxed or mailed to the Office using the appropriate Mail Stop (e.g., Mail Stop Pelition), if applicable. For transmittal of processing fees under 37 CFR 1.17(f), see form PTO/SB/17i.			
Payment of Fees (small entity amounts are NOT available for the p  X The Commissioner is hereby authorized to charge the following  X Petition foo under 37 CFR 1.17(f), (g) or (h)  Enclose a duplicative copy of this form for fee processing.  Check in the amount of \$ is enclosed.  Payment by credit card (Form PTO-2038 or equivalent enclosed.  Petition Fees under 37 CFR 1.17(f): Fee \$400 Fee Code 146 for publications filled under.  \$ 1.53(e) - In accord a filling date.  \$ 1.57(a) - to accord a filling date.  \$ 1.182 - for decision on a quesilion not specifically provided for.	otition fees).  g fees to Deposit Account No. 04-1105 : Any deficiency of fees and credit of any overpayments sed.  ed). Do not provide credit card information on this form.		
\$ 1.183 – to cuspend the rules. \$ 1.378(e) – for reconsideration of decision on petition refusing to accept delayed payment of maintenance fee in an expired potent. \$ 1.741(h) – to accord a filing date to an application under \$ 1.740 for extension of a patent term.  Petition Foos under 37 CFR 1.17(g): Fee \$200 Fee Code 1463  for politions filed under. \$ 1.12 – for access to an assignment record. \$ 1.14 – for inclose to an application. \$ 1.47 – for filing by other than all the inventors or a person not the inventor. \$ 1.50 – for expungement of information. \$ 1.103(a) – to suspend action in an application. \$ 1.138(b) – for review of a request for extension of time when the provisions of section 1.136(a) are not evaluable. \$ 1.208 – for review of refusal to publish a stabutory invention registration. \$ 1.377 – for review of decision refusing to accept and record payment of a maintenance fee filed prior to expiration of a patent. \$ 1.550(c) – for patent owner requests for extension of time in an appear reexamination proceedings. \$ 1.550 – for patent owner requests for extension of time in an appear reexamination proceedings. \$ 5.12 – for expedited handling of a foreign filing ilicense. \$ 5.15 – for changing the scope of a license. \$ 5.25 – for retinactive license.			
Petition Feos under 37 CFR 1.17(h): Foe \$130 Fee Code 1464  For petitions filed under  § 1.19(g) – to request documents in a farm other than that provided in this part.  § 1.84 – for accepting color drawings or photographs.  § 1.97 – for entry of a model or exhibit.  § 1.102(d) – to make an application special.  § 1.138(c) – to expressly abandon an application to avoid publication.  § 1.313 – to withdraw an application from Issue.  § 1.314 – to defor issuance of a patent.  January 20, 2006  Signature  Data			
Melissa Hunter-Ensor, Ph.D. Typed or printed name	55,289 Registration No., if applicable		

RECEIVED CENTRAL FAX CENTER

JAN 20 2006

(PATENT)

Docket No.: 62053ClP(51588)

I hereby curtify that this correspondence is being facsimile transmitted to the Palant and Trademark Office, facsimile no. (571) 273-8300, on the date shown

Dated: Junuary 20, 2006

(Eileen M. Woodbury)

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Mark C. Pozuansky et al.

Application No.: 10/002,854

Filed: November 1, 2001

For: CAR RECEPTOR AS A MEDIATOR OF

MIGRATORY CELL CHEMOTAXIS AND/OR

CHEMOKINESIS

Confirmation No.: 3669

Art Unit: 1651

Examiner: L. B. Lankford

### PETITION UNDER 37 CFR 1,181

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicants hereby petition the Commissioner for Patents under 37 CFR 1.181 to withdraw the finality of the office action mailed March 30, 2005 in application serial number 10/002,854. Applicants further petition under 37 CFR 1.183 to suspend the rule requiring a request for reconsideration under 37 CFR 1.111, in the event that the Commissioner deems it necessary in these circumstances. The Applicants believe that the extraordinary circumstances set forth below warrant grant of this combined petition.

#### Statement of facts

The Office mailed a final rejection in the above-referenced case (US Serial Number 10/002,854) on March 30, 2005. In response, Applicants timely filed an amendment under 37 CFR 1.116 on June 30, 2005. Applicants' attorney phoned the Examiner on July 27, 2005 to discuss the amendment and was informed that the amendment did not place the application in condition for allowance and that an Advisory Action would be forthcoming. Applicants then filed a Notice of Appeal on 8/1/2005. Applicants' attorney placed several subsequent telephone

01/23/2006 MBINAS

00000045 041105

19992854

01 FC:1462

400.00 DA

527047

Application No. 10/002,854

Docket No.: 62053CIP(51588)

calls inquiring as to the status of the application and when an Advisory Action would be mailed. The Advisory Action and Telephone Summary Record inviting a subsequent interview were not mailed until December 8, 2005, over five (5) months from the date of Applicants' amendment. The reason(s) for the Office delay is unclear. Further, the Advisory Action failed to note whether the Applicants' amendment had been entered (See Advisory Action mailed December 8, 2005; item 7 where neither box (a) nor box (b) is checked). However, as has been subsequently learned from checking the public PAIR site, the first page of Applicants Amendment after final shows the Examiner's initials beneath the words "OK to enter" in the margin. Thus, while Applicants may now presumably assume that the amendment was entered for the purposes of appeal, it is undisputed that this information was not timely communicated to the Applicants.

During a recent phone conversation with the Examiner on January 6, 2006, the Examiner indicated that, while he sympathized with the Applicants for the difficulties caused by the substantial Office delay in issuing the Advisory Action, he lacked the grounds to restart the period for reply and that the only recourse would be for Applicants to file an RCE. Applicants respectfully request that the Office reconsider its decision to maintain the finality of the Office action and to restart the shortened statutory period for response.

#### Issues in Examination

As of the final rejection, the only rejection of remaining was under 35 USC 103 over Yamaguchi et al, (*J. Bone Min. Research* Vol. 10(13)1530, 1998) which was directed to the in vitro investigations of certain compounds on MC3T3-E1 cells derived from mouse calvaria and having an osteoblast-like phenotype. In an effort to clarify the invention, the amendment narrowed the claims to hematopoietic cells distinguishing the invention from Yamaguchi et al. The Advisory Action asserted that the amendment was unsuccessful in avoiding the rejection because "Applicant argues that there is no reasonable expectation of success to extrapolate the Yamaguchi reference teachings to the in vivo effect on hematopoietic cells however it is unclear where applicant has demonstrated this and applicant would seem to depend on a like extrapolation with only a suggestion of in vivo use." See Advisory Action; continuation of 11. In fact, the application, as originally filed, contains in vitro and in vivo data and evidence directed to the impact of compounds on hematopoietic cells, in particular monocytes, as well as

527047

Application No. 10/002,854

Docket No.: 62053CIP(\$1588)

in vitro data on peripheral blood cells and hematopoietic progenitor cells (all hematopoietic cells). Thus, the Examiner's reason for maintaining the rejection is technically flawed. Indeed, the Interview Summary Record of July 27, 2005 invited a subsequent interview, presumably to discuss the merits of the statements in the Advisory Action. However, because of the delay in advising the Applicants of the grounds for maintaining the rejections, Applicants have been procedurally denied the opportunity to correct the technical misunderstanding. This is not the fault of Applicants or caused by the Applicants delay. It is caused by the PTO delay in mailing the Advisory Action.

#### Action requested by Applicants

In light of Office's failure to timely mail a complete advisory action within the required timeframe, and the refusal to remedy the problem by restarting the period for reply, Applicants request that the Director grant the instant petitions.

... The lateness and cryptic nature of the Advisory Action has consequently precluded Applicant from making a timely request for reconsideration as required by 37 CFR 1.116 to process. correct the apparent technical misunderstandings made by the Examiner as to the content of the Barbara and the Barba specification. Applicants should have been entitled to have such arguments presented in a second submission under 37 CFR 1.116 as they were raised for the first time in the Advisory Action. Applicants could not have anticipated that the Examiner would apparently mistakenly conclude (1) that in vitro studies of an ostcoblastic-like clonal cell line derived from calvaria (not marrow) would render obvious in vivo studies of hematopoietic cells or (2) that that monocytes, peripheral blood cells and hematopoietic progenitor cells are not hematopoietic cells. Further, the lateness and incomplete nature of the Advisory Action has obviously frustrated the Applicants' ability to prepare a convincing and meaningful brief on appeal. For instance, the status of the entry of the amendment and the claims to be appealed has only been recently revealed to the Applicants. Of course, any brief on appeal must present arguments relevant to the appealed claims. In this case, since the Examiner's rejection, as maintained in the Advisory Action, appears to contain a fundamental technical misunderstanding, the issues on appeal cannot yet be said to be ripe. Further, these substantial delays will be assumed to be Applicant delays for the purposes of patent term adjustment if the Applicant pursues the appeal and filing

527047

Application No. 10/002,854

Docket No.: 62053C(P(51588)

an RCE will completely climinate the substantial Office delays that have been incurred to date. The loss of term where the Applicant has been very diligent is fundamentally unfair. This situation is not unlike the situation set forth in MPEP Section 710.06 where an office action is defective (for example, omitting an indication that an amendment was entered). In these cases, the MPEP suggests that the shortened statutory period for reply be restarted. Applicants, in contacting the Examiner on September 21, 2005, October 27, 2005, and November 1, 2005, have timely pointed out the omissions in the Advisory Action and the undue delay in receiving the Action. This petition follows the Examiner's denial of Applicants' request.

Applicants therefore respectfully request that in the interest of equity, the Director in his discretion grant Applicants' petition, order that the finality of the last action by the Office be withdrawn and that the Office issue a new Action restarting the statutory period for reply, and preserving Applicants' earned patent term adjustments.

The Director is hereby authorized to charge the fee set forth under 37 CFR 1.17(f)in the amount of \$400.00 to Deposit Account No. 04-1105. No additional fee is believed due to consider this position; however, the Director is hereby authorized to charge any deficiency or discovered that any overpayment in the fees filed, asserted to be filed or which should have been filed therewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62053 (51588).

Dated: January 20, 2006

Respectfully submitted,

Melissa Hunter-Ensor, Ph.D. Registration No. 55 289

Registration No.: 55,289

EDWARDS ANGELL PALMER & DODGE

LLP

Three Stamford Plaza
301 Tresser Boulevard
Suite 1310
Stamford, Connecticut 06901

(617) 439-4444

Attorneys/Agents For Applicant

62/04/